VEGFA and metastatic neoplasm: Although targeted therapies such as vascular endothelial growth factor (VEGF) and mammalian target of rapamycin inhibitors have improved clinical outcomes, approximately 33% of patients still progress to metastatic disease, with a 5-year survival of only 12%.3